Crohn's disease

The Lancet

Volumn 389, Issue 10080, 2017, Pages 1741-1755

  Torres, Joana ^a   Mehandru, Saurabh ^a   Colombel, Jean Frédéric ^a   Peyrin Biroulet, Laurent ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; CHRONIC DIARRHEA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FATIGUE; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTESTINE FLORA; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK FACTOR; WEIGHT REDUCTION; DISEASE EXACERBATION; DISEASE MANAGEMENT; DRUG MONITORING; PROCEDURES;

BIOLOGICAL PRODUCTS; CROHN DISEASE; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG MONITORING; HUMANS; REMISSION INDUCTION; RISK FACTORS;

EID: 85007453723     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31711-1     Document Type: Review

References (149)

1. 1 Thia, KT, Sandborn, WJ, Harmsen, WS, Zinsmeister, AR, Loftus, EV, Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 139 (2010), 1147–1155.
2. 2 Peyrin-Biroulet, L, Loftus, EV, Colombel, JF, Sandborn, WJ, The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 105 (2010), 289–297.
3. 3 Molodecky, NA, Soon, IS, Rabi, DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.e42 quiz e30.
4. 4 Ng, SC, Tang, W, Ching, JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 145 (2013), 158–165.e2.
5. 5 Benchimol, EI, Mack, DR, Guttmann, A, et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol 110 (2015), 553–563.
6. 6 Moller, FT, Andersen, V, Wohlfahrt, J, Jess, T, Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. Am J Gastroenterol 110 (2015), 564–571.
7. 7 Ananthakrishnan, AN, Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12 (2015), 205–217.
8. 8 Huang, C, Haritunians, T, Okou, DT, et al. Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology 149 (2015), 1575–1586.
9. 9 Jostins, L, Ripke, S, Weersma, RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
10. 10 Liu, JZ, van Sommeren, S, Huang, H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47 (2015), 979–986.
11. 11 McGovern, DP, Kugathasan, S, Cho, JH, Genetics of inflammatory bowel diseases. Gastroenterology 149 (2015), 1163–1176.e2.
12. 12 Torres, J, Colombel, JF, Genetics and phenotypes in inflammatory bowel disease. Lancet 387 (2016), 98–100.
13. 13 Bernstein, CN, Banerjee, A, Targownik, LE, et al. Cesarean section delivery is not a risk factor for development of inflammatory bowel disease: a population-based analysis. Clin Gastroenterol Hepatol 14 (2016), 50–57.
14. 14 Mahid, SS, Minor, KS, Soto, RE, Hornung, CA, Galandiuk, S, Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 81 (2006), 1462–1471.
15. 15 Ungaro, R, Bernstein, CN, Gearry, R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 109 (2014), 1728–1738.
16. 16 Cornish, JA, Tan, E, Simillis, C, Clark, SK, Teare, J, Tekkis, PP, The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 103 (2008), 2394–2400.
17. 17 Ananthakrishnan, AN, Higuchi, LM, Huang, ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 156 (2012), 350–359.
18. 18 Ungaro, R, Chang, HL, Cote-Daigneaut, J, Mehandru, S, Atreja, A, Colombel, JF, Statins associated with decreased risk of new onset inflammatory bowel disease. Am J Gastroenterol 111 (2016), 1416–1423.
19. 19 Ananthakrishnan, AN, Khalili, H, Konijeti, GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut 63 (2014), 776–784.
20. 20 Bernstein, CN, Shanahan, F, Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57 (2008), 1185–1191.
21. 21 Ng, SC, Tang, W, Leong, RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 64 (2015), 1063–1071.
22. 22 Kostic, AD, Xavier, RJ, Gevers, D, The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146 (2014), 1489–1499.
23. 23 Darfeuille-Michaud, A, Boudeau, J, Bulois, P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2004), 412–421.
24. 24 Lapaquette, P, Glasser, AL, Huett, A, Xavier, RJ, Darfeuille-Michaud, A, Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol 12 (2010), 99–113.
25. 25 Sokol, H, Pigneur, B, Watterlot, L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105 (2008), 16731–16736.
26. 26 Quévrain, E, Maubert, MA, Michon, C, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65 (2016), 415–425.
27. 27 Norman, JM, Handley, SA, Baldridge, MT, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160 (2015), 447–460.
28. 28 Sokol, H, Leducq, V, Aschard, H, et al. Fungal microbiota dysbiosis in IBD. Gut, 2016, 10.1136/gutjnl-2015-310746 published online Feb 3.
29. 29 Vaishnava, S, Yamamoto, M, Severson, KM, et al. The antibacterial lectin RegIIIγ promotes the spatial segregation of microbiota and host in the intestine. Science 334 (2011), 255–258.
30. 30 Chassaing, B, Koren, O, Goodrich, JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519 (2015), 92–96.
31. 31 Boltin, D, Perets, TT, Vilkin, A, Niv, Y, Mucin function in inflammatory bowel disease: an update. J Clin Gastroenterol 47 (2013), 106–111.
32. 32 Levine, B, Mizushima, N, Virgin, HW, Autophagy in immunity and inflammation. Nature 469 (2011), 323–335.
33. 33 Benjamin, JL, Sumpter, R, Levine, B, Hooper, LV, Intestinal epithelial autophagy is essential for host defense against invasive bacteria. Cell Host Microbe 13 (2013), 723–734.
34. 34 Zeissig, S, Bürgel, N, Günzel, D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56 (2007), 61–72.
35. 35 Hart, AL, Al-Hassi, HO, Rigby, RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129 (2005), 50–65.
36. 36 Bain, CC, Mowat, AM, Macrophages in intestinal homeostasis and inflammation. Immunol Rev 260 (2014), 102–117.
37. 37 Qiu, J, Guo, X, Chen, ZM, et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39 (2013), 386–399.
38. 38 Qiu, J, Heller, JJ, Guo, X, et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 36 (2012), 92–104.
39. 39 Bernink, JH, Peters, CP, Munneke, M, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 14 (2013), 221–229.
40. 40 Geremia, A, Arancibia-Cárcamo, CV, Fleming, MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208 (2011), 1127–1133.
41. 41 Satoh-Takayama, N, Vosshenrich, CA, Lesjean-Pottier, S, et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29 (2008), 958–970.
42. 42 Ouellette, AJ, Paneth cells and innate mucosal immunity. Curr Opin Gastroenterol 26 (2010), 547–553.
43. 43 Hirahara, K, Nakayama, T, CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol 28 (2016), 163–171.
44. 44 Hansen, JJ, Immune responses to intestinal microbes in inflammatory bowel diseases. Curr Allergy Asthma Rep, 15, 2015, 61.
45. 45 Maloy, KJ, Powrie, F, Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474 (2011), 298–306.
46. 46 Brandtzaeg, P, Carlsen, HS, Halstensen, TS, The B-cell system in inflammatory bowel disease. Adv Exp Med Biol 579 (2006), 149–167.
47. 47 Mora, JR, Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids. Inflamm Bowel Dis 14 (2008), 275–289.
48. 48 Eglinton, TW, Barclay, ML, Gearry, RB, Frizelle, FA, The spectrum of perianal Crohn's disease in a population-based cohort. Dis Colon Rectum 55 (2012), 773–777.
49. 49 Magro, F, Langner, C, Driessen, A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7 (2013), 827–851.
50. 50 Zhao, XS, Wang, ZT, Wu, ZY, et al. Differentiation of Crohn's disease from intestinal tuberculosis by clinical and CT enterographic models. Inflamm Bowel Dis 20 (2014), 916–925.
51. 51 Grigg, EL, Kane, S, Katz, S, Mimicry and deception in inflammatory bowel disease and intestinal Behçet disease. Gastroenterol Hepatol (N Y) 8 (2012), 103–112.
52. 52 Wang, YZ, Sun, G, Cai, FC, Yang, YS, Clinical features, diagnosis, and treatment strategies of gastrointestinal diaphragm disease associated with nonsteroidal anti-inflammatory drugs. Gastroenterol Res Pract, 2016, 2016, 3679741.
53. 53 Levine, A, Griffiths, A, Markowitz, J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 17 (2011), 1314–1321.
54. 54 Satsangi, J, Silverberg, MS, Vermeire, S, Colombel, JF, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006), 749–753.
55. 55 Mosli, MH, Zou, G, Garg, SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110 (2015), 802–819.
56. 56 Vermeire, S, Peeters, M, Vlietinck, R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 7 (2001), 8–15.
57. 57 Dubinsky, MC, Kugathasan, S, Mei, L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 6 (2008), 1105–1111.
58. 58 Menees, SB, Powell, C, Kurlander, J, Goel, A, Chey, WD, A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 110 (2015), 444–454.
59. 59 van Rheenen, PF, Van de Vijver, E, Fidler, V, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ, 341, 2010, c3369.
60. 60 Wright, EK, Kamm, MA, De Cruz, P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology, 148, 2015, 938 47.e1.
61. 61 Kristensen, V, Moum, B, Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease. Scand J Gastroenterol 50 (2015), 1183–1184.
62. 62 Annese, V, Daperno, M, Rutter, MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7 (2013), 982–1018.
63. 63 Feakins, RM, British Society of Gastroenterology. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol 66 (2013), 1005–1026.
64. 64 Ordás, I, Rimola, J, Rodríguez, S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology, 146, 2014, 374 82.e1.
65. 65 Panes, J, Bouhnik, Y, Reinisch, W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 7 (2013), 556–585.
66. 66 Pariente, B, Mary, JY, Danese, S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology 148 (2015), 52–63.e3.
67. 67 Panés, J, Bouzas, R, Chaparro, M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 34 (2011), 125–145.
68. 68 Van Assche, G, Dignass, A, Reinisch, W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 4 (2010), 63–101.
69. 69 Vuitton, L, Marteau, P, Sandborn, WJ, et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 65 (2016), 1447–1455.
70. 70 Siegel, CA, Whitman, CB, Spiegel, BM, et al. Development of an index to define overall disease severity in IBD. Gut, 2016, 10.1136/gutjnl-2016-312648 published online Oct 25.
71. 71 Peyrin-Biroulet, L, Reinisch, W, Colombel, JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 63 (2014), 88–95.
72. 72 Pariente, B, Cosnes, J, Danese, S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 17 (2011), 1415–1422.
73. 73 Bakan, S, Olgun, DC, Kandemirli, SG, et al. Perianal fistula with and without abscess: assessment of fistula activity using diffusion-weighted magnetic resonance imaging. Iran J Radiol, 12, 2015, e29084.
74. 74 Louis, E, Collard, A, Oger, AF, Degroote, E, Aboul Nasr El Yafi, FA, Belaiche, J, Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001), 777–782.
75. 75 Cosnes, J, Bourrier, A, Nion-Larmurier, I, Sokol, H, Beaugerie, L, Seksik, P, Factors affecting outcomes in Crohn's disease over 15 years. Gut 61 (2012), 1140–1145.
76. 76 Limketkai, BN, Parian, AM, Shah, ND, Colombel, JF, Short bowel syndrome and intestinal failure in Crohn's Disease. Inflamm Bowel Dis 22 (2016), 1209–1218.
77. 77 Buisson, A, Chevaux, JB, Allen, PB, Bommelaer, G, Peyrin-Biroulet, L, Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 35 (2012), 625–633.
78. 78 Zallot, C, Peyrin-Biroulet, L, Clinical risk factors for complicated disease: how reliable are they?. Dig Dis 30:suppl 3 (2012), 67–72.
79. 79 Vuitton, L, Koch, S, Peyrin-Biroulet, L, Preventing postoperative recurrence in Crohn's disease: what does the future hold?. Drugs 73 (2013), 1749–1759.
80. 80 Ryan, JD, Silverberg, MS, Xu, W, et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 38 (2013), 274–283.
81. 81 Cleynen, I, Boucher, G, Jostins, L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387 (2016), 156–167.
82. 82 Lee, JC, Lyons, PA, McKinney, EF, et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 121 (2011), 4170–4179.
83. 83 Siegel, CA, Horton, H, Siegel, LS, et al. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther 43 (2016), 262–271.
84. 84 Beaugerie, L, Itzkowitz, SH, Cancers complicating inflammatory bowel disease. N Engl J Med, 373, 2015, 195.
85. 85 Annese, V, Beaugerie, L, Egan, L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9 (2015), 945–965.
86. 86 Shah, SC, Colombel, JF, Sands, BE, Narula, N, Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 43 (2016), 317–333.
87. 87 Peyrin-Biroulet, L, Fiorino, G, Buisson, A, Danese, S, First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. Nat Rev Gastroenterol Hepatol 10 (2013), 345–351.
88. 88 Khanna, R, Bressler, B, Levesque, BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386 (2015), 1825–1834.
89. 89 NICE. Infliximab and adalimumab for the treatment of Crohn's disease. https://www.nice.org.uk/guidance/TA187, 2010 (accessed June 23, 2016).
90. 90 Danese, S, Vuitton, L, Peyrin-Biroulet, L, Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 12 (2015), 537–545.
91. 91 Ford, AC, Khan, KJ, Talley, NJ, Moayyedi, P, 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 106 (2011), 413–420.
92. 92 Prantera, C, Lochs, H, Grimaldi, M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology, 142, 2012, 473 81.e4.
93. 93 Dignass, A, Van Assche, G, Lindsay, JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 4 (2010), 28–62.
94. 94 Rezaie, A, Kuenzig, ME, Benchimol, EI, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 6, 2015 CD000296.
95. 95 Faubion, WA, Loftus, EV, Harmsen, WS, Zinsmeister, AR, Sandborn, WJ, The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001), 255–260.
96. 96 Benchimol, EI, Seow, CH, Otley, AR, Steinhart, AH, Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev, 1, 2009 CD002913.
97. 97 Benchimol, EI, Seow, CH, Steinhart, AH, Griffiths, AM, Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 2, 2008 CD006792.
98. 98 Ruemmele, FM, Veres, G, Kolho, KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 8 (2014), 1179–1207.
99. 99 Zachos, M, Tondeur, M, Griffiths, AM, Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 1, 2007 CD000542.
100. 100 Chande, N, Patton, PH, Tsoulis, DJ, Thomas, BS, MacDonald, JK, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev, 10, 2015 CD000067.
101. 101 McDonald, JW, Wang, Y, Tsoulis, DJ, MacDonald, JK, Feagan, BG, Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev, 8, 2014 CD003459.
102. 102 Patel, V, Wang, Y, MacDonald, JK, McDonald, JW, Chande, N, Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev, 8, 2014 CD006884.
103. 103 Peyrin-Biroulet, L, Oussalah, A, Williet, N, Pillot, C, Bresler, L, Bigard, MA, Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 60 (2011), 930–936.
104. 104 Ramadas, AV, Gunesh, S, Thomas, GA, Williams, GT, Hawthorne, AB, Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 59 (2010), 1200–1206.
105. 105 Cosnes, J, Bourrier, A, Laharie, D, et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology, 145, 2013, 758 65.e2 quiz e14.
106. 106 Panés, J, López-Sanromán, A, Bermejo, F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology, 145, 2013, 766 74.e1.
107. 107 Peyrin-Biroulet, L, Khosrotehrani, K, Carrat, F, et al. Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology, 141, 2011, 1621 28.e1.
108. 108 Beaugerie, L, Brousse, N, Bouvier, AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374 (2009), 1617–1625.
109. 109 Bourrier, A, Carrat, F, Colombel, JF, et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther 43 (2016), 252–261.
110. 110 Moon, W, Loftus, EV, Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther, 2016, 10.1111/apt.13559 published online Feb 14.
111. 111 Feagan, BG, Fedorak, RN, Irvine, EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 (2000), 1627–1632.
112. 112 Laharie, D, Zerbib, F, Adhoute, X, et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 23 (2006), 1621–1628.
113. 113 Feagan, BG, McDonald, JW, Panaccione, R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology, 146, 2014, 681 88.e1.
114. 114 Sands, BE, Anderson, FH, Bernstein, CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004), 876–885.
115. 115 Colombel, JF, Schwartz, DA, Sandborn, WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58 (2009), 940–948.
116. 116 Gecse, KB, Bemelman, W, Kamm, MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut 63 (2014), 1381–1392.
117. 117 Papamichael, K, Van Stappen, T, Jairath, V, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther 42 (2015), 1158–1169.
118. 118 Colombel, JF, Sandborn, WJ, Reinisch, W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
119. 119 Matsumoto, T, Motoya, S, Watanabe, K, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial. J Crohns Colitis 10 (2016), 1259–1266.
120. 120 Ben-Horin, S, Waterman, M, Kopylov, U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11 (2013), 444–447.
121. 121 Ford, AC, Peyrin-Biroulet, L, Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108 (2013), 1268–1276.
122. 122 Dulai, PS, Siegel, CA, Colombel, JF, Sandborn, WJ, Peyrin-Biroulet, L, Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut 63 (2014), 1843–1853.
123. 123 Deepak, P, Sifuentes, H, Sherid, M, Stobaugh, D, Sadozai, Y, Ehrenpreis, ED, T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 108 (2013), 99–105.
124. 124 Sandborn, WJ, Feagan, BG, Rutgeerts, P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369 (2013), 711–721.
125. 125 Sands, BE, Feagan, BG, Rutgeerts, P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology, 147, 2014, 618 27.e3.
126. 126 Sandborn, WJ, Gasink, C, Gao, LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367 (2012), 1519–1528.
127. 127 Sandborn, W, Gasink, C, Blank, M, et al. O-001 a multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn's disease refractory to anti-TFNα: UNITI-1. Inflamm Bowel Dis, 22(suppl 1), 2016, S1.
128. 128 Strong, S, Steele, SR, Boutrous, M, et al. Clinical practice guideline for the surgical management of Crohn's disease. Dis Colon Rectum 58 (2015), 1021–1036.
129. 129 Spinelli, A, Allocca, M, Jovani, M, Danese, S, Review article: optimal preparation for surgery in Crohn's disease. Aliment Pharmacol Ther 40 (2014), 1009–1022.
130. 130 Holder-Murray, J, Marsicovetere, P, Holubar, SD, Minimally invasive surgery for inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 1443–1458.
131. 131 O'Toole, A, Nwanne, O, Tomlinson, T, Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. Dig Dis Sci 60 (2015), 2750–2761.
132. 132 McConnell, RA, Mahadevan, U, Pregnancy and the patient with inflammatory bowel disease: fertility, treatment, delivery, and complications. Gastroenterol Clin North Am 45 (2016), 285–301.
133. 133 Nguyen, GC, Seow, CH, Maxwell, C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology, 150, 2016, 734 57.e1.
134. 134 Mahadevan, U, Martin, CF, Sandler, RS, et al. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology, 142, 2012, S149.
135. 135 Mahadevan, U, Wolf, DC, Dubinsky, M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11 (2013), 286–292.
136. 136 van der Woude, CJ, Ardizzone, S, Bengtson, MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 9 (2015), 107–124.
137. 137 Schreiber, S, Colombel, JF, Bloomfield, R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 105 (2010), 1574–1582.
138. 138 Pineton de Chambrun, G, Blanc, P, Peyrin-Biroulet, L, Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 10 (2016), 915–927.
139. 139 Mosli, MH, Sandborn, WJ, Kim, RB, Khanna, R, Al-Judaibi, B, Feagan, BG, Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol 109 (2014), 994–1004.
140. 140 Song, GG, Seo, YH, Kim, JH, Choi, SJ, Ji, JD, Lee, YH, Association between TNF-α (−308 A/G, −238 A/G, −857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. Pharmacogenomics 16 (2015), 1427–1437.
141. 141 Vande Casteele, N, Ferrante, M, Van Assche, G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology, 148, 2015, 1320 29.e3.
142. 142 D'Haens, G, Vermeire, S, Lambrecht, G, et al. OP029. Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix). J Crohns Colitis, 10, 2016, S24.1 S2S24.
143. 143 Steenholdt, C, Brynskov, J, Thomsen, OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63 (2014), 919–927.
144. 144 Torres, J, Boyapati, RK, Kennedy, NA, Louis, E, Colombel, JF, Satsangi, J, Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 149 (2015), 1716–1730.
145. 145 Louis, E, Mary, JY, Vernier-Massouille, G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142 (2012), 63–70.e5 quiz e31.
146. 146 Monteleone, G, Neurath, MF, Ardizzone, S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 372 (2015), 1104–1113.
147. 147 Danese, S, Grisham, M, Hodge, J, Telliez, JB, JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 310 (2016), G155–G162.
148. 148 Panés, J, García-Olmo, D, Van Assche, G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 388 (2016), 1281–1290.
149. 149 Torres, J, Burisch, J, Riddle, M, Dubinsky, M, Colombel, JF, Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut 65 (2016), 1061–1069.